In our previous study, we found that Nimotuzumab could increase ESCC chemosensitivity to DDP by upregulating IGFBP-3 expression through EGFR-dependent pathway in vitro[20]. This evidence concerns the gene EGFR and esophageal squamous cell carcinoma.